

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number		10596725
	Filing Date		
	First Named Inventor	SusanneAlenfolk	
	Art Unit		
	Examiner Name		
Attorney Docket Number		ASZN0106-100 101342-1P US	

U.S.PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	5767115		1998-06-16	Rosenblum et al.	
	2	5306817		1994-04-26	Thiruvengadam et al.	
	3	5846966		1998-12-08	Rosenblum et al.	
	4	5631365		1997-05-20	Rosenblum et al.	
	5	5739321		1998-04-14	Wu et al.	
	6	5756470		1998-05-26	Yumibe et al.	
	7	5886171		1999-03-23	Wu et al.	
	8	5919672		1999-07-06	Homann et al.	

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10596725
Filing Date	
First Named Inventor	SusanneAlenfolk
Art Unit	
Examiner Name	
Attorney Docket Number	ASZN0106-100 101342-1P US

9	RE37721		2002-05-28	Rosenblum et al.	
---	---------	--	------------	------------------	--

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

**U.S. PATENT APPLICATION PUBLICATIONS**

Remove

Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	20020137690		2002-09-26	Ghosal et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

**FOREIGN PATENT DOCUMENTS**

Remove

Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> j	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1	524595	EP		1993-01-27	Schering Corporation		<input type="checkbox"/>
	2	2004005247	WO		2004-01-15	AstraZeneca UK LTD.		<input type="checkbox"/>
	3	0250060	WO		2002-06-27	Avantis Pharma Deutschland GMBH		<input type="checkbox"/>
	4	2004081002	WO		2004-09-23	Schering Corporation		<input type="checkbox"/>
	5	9501961	WO		1995-01-19	Schering Corporation		<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number		10596725
Filing Date		
First Named Inventor	SusanneAlenfalk	
Art Unit		
Examiner Name		
Attorney Docket Number	ASZN0106-100 101342-1P US	

6	9508532	WO		1995-03-30	Schering Corporation		<input type="checkbox"/>
7	9414433	WO		1994-07-07	Schering Corporation		<input type="checkbox"/>
8	9302048	WO		1993-02-04	Schering Corporation		<input type="checkbox"/>
9	9417038	WO		1994-08-04	Schering Corporation		<input type="checkbox"/>
10	9526334	WO		1995-10-05	Schering Corporation		<input type="checkbox"/>
11	9609827	WO		1996-04-04	Pfizer Inc.		<input type="checkbox"/>
12	9616037	WO		1996-05-30	Schering Corporation		<input type="checkbox"/>
13	9535277	WO		1995-12-28	Schering Corporation		<input type="checkbox"/>
14	02058685	WO		2002-08-01	Schering Corporation		<input type="checkbox"/>
15	9745406	WO		1997-12-04	Schering Corporation		<input type="checkbox"/>
16	0038725	WO		2000-07-06	G.D. Searle & Co.		<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number		10596725
Filing Date		
First Named Inventor	SusanneAlenfalk	
Art Unit		
Examiner Name		
Attorney Docket Number	ASZN0106-100 101342-1P US	

17	02058696	WO		2002-08-01	Schering Corporation		<input type="checkbox"/>
18	0250027	WO		2002-06-27	Aventis Pharma Deutschland		<input type="checkbox"/>
19	0250090	WO		2002-06-27	Schering Corporation		<input type="checkbox"/>
20	9619450	WO		1996-06-27	Schering Corporation		<input type="checkbox"/>
21	0063703	WO		2000-10-26	Schering Corporation		<input type="checkbox"/>
22	9716455	WO		1997-05-09	Schering Corporation		<input type="checkbox"/>
23	0020623	WO		2000-04-13	Schering Corporation		<input type="checkbox"/>
24	0034240	WO		2000-06-15	Schering Corporation		<input type="checkbox"/>
25	0060107	WO		2000-10-12	Schering Corporation		<input type="checkbox"/>
26	0250068	WO		2002-06-27	Aventis Pharma Deutschland		<input type="checkbox"/>
27	9716424	WO		1997-05-09	Schering Corporation		<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number		10596725
Filing Date		
First Named Inventor	SusanneAlenfolk	
Art Unit		
Examiner Name		
Attorney Docket Number	ASZN0106-100 101342-1P US	

28	0218432	WO		2002-03-07	Aventis Pharma Deutschland		<input type="checkbox"/>
29	02058731	WO		2002-08-01	Schering Corporation		<input type="checkbox"/>
30	02058732	WO		2002-08-01	Schering Corporation		<input type="checkbox"/>
31	02058733	WO		2002-08-01	Schering Corporation		<input type="checkbox"/>
32	02058734	WO		2002-08-01	Schering Corporation		<input type="checkbox"/>
33	02066464	WO		2002-08-29	Kotobuki Pharmaceutical Co.		<input type="checkbox"/>
34	02072104	WO		2002-09-19	Merck & Co., Inc.		<input type="checkbox"/>
35	02079174	WO		2002-10-10	Schering Corporation		<input type="checkbox"/>
36	02096415	WO		2002-12-05	Schering Corporation		<input type="checkbox"/>
37	03026644	WO		2003-04-03	Schering Corporation		<input type="checkbox"/>
38	03088962	WO		2003-10-30	Merck & Co., Inc.		<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10596725
Filing Date	
First Named Inventor	SusanneAlenfolk
Art Unit	
Examiner Name	
Attorney Docket Number	ASZN0106-100 101342-1P US

39	2004000803	WO		2003-12-31	Aventis Pharma Deutschland		<input type="checkbox"/>
40	2004000804	WO		2003-12-31	Aventis Pharma Deutschland		<input type="checkbox"/>
41	2004000805	WO		2003-12-31	Aventis Pharma Deutschland		<input type="checkbox"/>
42	2004010993	WO		2004-02-05	Merck Sharp & Dohme Limited		<input type="checkbox"/>
43	2004010948	WO		2004-02-05	Karykion Inc.		<input type="checkbox"/>
44	2004014947	WO		2004-02-19	Aventis Pharma Deutschland		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

**NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
	1	Vaccaro et al., "Carboxy-substituted 2-azetidinones as cholesterol absorption inhibitors," Bioorganic & Med Chem Letters (1998) 8(3):319-322.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

**EXAMINER SIGNATURE**

Examiner Signature	/Mark Berch/ (07/14/2009)	Date Considered	
--------------------	---------------------------	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.